REGN Regeneron Pharmaceuticals, Inc.

Range, yield & payout streak

Insufficient full-year dividend history to compute streak.

BDC / cash pass-through vs ordinary dividend

Ordinary corporate dividend — paid from corporate earnings/cash at the board’s discretion. Unlike BDCs/REITs, there is usually no pass-through distribution mandate. Coverage (earnings/FCF vs dividend), balance sheet, and streak matter more than yield height.

Remember: high yield ≠ safer. Pass-through vehicles (BDC / REIT) can show high distributions by design while carrying credit, rate, or occupancy risk.

Dividend safety rating

High yield ≠ safer — elevated yield often prices higher risk or return-of-capital. Yahoo payoutRatio raw=0.090100005 (interpret cautiously).

Dividend history trend (recent payments)

Sourced from Yahoo via yfinance. Gaps or missing rows = data unavailable, not zeroes we invented.

Pass-through / BDC mechanics (deeper)

Ordinary corporate dividend — paid from corporate earnings/cash at the board’s discretion. Unlike BDCs/REITs, there is usually no pass-through distribution mandate. Coverage (earnings/FCF vs dividend), balance sheet, and streak matter more than yield height.

Advanced frame: for ordinary payers, focus on earnings/FCF coverage and balance-sheet flexibility. For REITs, focus on AFFO/FFO trends, occupancy, and debt ladders. For BDCs, focus on NII vs distribution, non-accruals, leverage vs statutory limits, and NAV drift. This page still is not a Crystal Signals entry card — no Counsel fire / manage stamp here.

Full company blurb

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.